Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Chikungunya: What Every Rheumatologist Needs to Know

Dany V. Thekkemuriyil, MD  |  Issue: November 2014  |  November 2, 2014

Polyarthritis is reported in 87–98% of cases, typically seen two to five days after onset of fever. They are commonly symmetrical (64–73%), with pain and swelling involving distal small joints such as those of the hands, wrists and ankles. Involvement of the axial skeleton was noted in 34–52% of cases.8,23,24 Often, the arthritis is severe and debilitating, leading to immobilization due to pain. The subsequent phase of persistent arthritis/arthralgias is unique with Chikungunya. This phase is characterized by morning stiffness, persistent joint pain and swelling, which may last for months to years. One study from South Africa reports arthritis occurring eight years after the acute illness.25 The number of individuals with persistent joint symptoms decreases with time.

These symptoms mimic rheumatoid arthritis (RA), and case reports from the Reunion Island outbreak have reported 21 patients fulfilling the American College of Rheumatology (ACR) criteria for RA.26 Another study from India showed 36% (34/94) met the ACR criteria for RA, of whom only one individual tested positive for anticyclic citrullinated peptide.27 Tenosynovitis is another commonly described feature.28 Lymphopenia and moderate thrombocytopenia are observed on laboratory tests. An elevated sedimentation rate or C-reactive protein is not frequently seen. A small number of cases from India, as well as the Reunion Islands, has documented radiographic erosions on magnetic resonance imaging during the persistent arthritic phase.27,28

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Can Chikungunya Infection Be Fatal?

Severe complications and death are reported among patients older than 65 years, infants and in those with other underlying co-morbid illnesses. A case–fatality ratio of about 1:1,000 was documented from the Reunion Islands.29 Uveitis, myocarditis, hepatitis, nephritis, meningoencephalitis, Guillain-Barré syndrome and cranial nerve palsies have also been reported with Chikungunya infection.6,8,30,31 Thus, chances for severe complications are higher in immunocompromised individuals. There has not been any clear report about Chikungunya in immunosuppressed individuals, but it would be concerning in those who are on immunosuppressive treatment. In utero transmission has been documented, mostly during the second trimester, as well as intrapartum transmission. In a case report from the Reunion Islands, severe illness was observed in 53% of newborns and mainly consisted of encephalo­pathy with persistent disabilities in 44% of them.32

How to Diagnose Chikungunya?

The primary diagnostic tool is testing for IgM anti-Chikungunya virus antibodies (by enzyme-linked immunosorbent assay [ELISA]). They are detected in the serum starting about four days following onset of symptoms. IgG antibodies are detected after about two weeks and may persist for years. CHIKV diagnostic testing in the U.S. is primarily only performed by the Centers for Disease Control and Prevention (CDC). Testing for these antibodies is not very specific, and cross-reactivity with other alphaviruses has been noted. Reverse-transcription polymerase chain reaction (RT-PCR) can be used as a diagnostic tool during the initial viremic phase (≤8 days). Viral cultures are used as a research tool and may detect the virus in the first three days of illness. CHIKV has been isolated from biopsies of skeletal muscles, synovial tissue and skin, and has also been found in perivascular synovial macrophages.33

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Treatment

There has not been much evidence-based research regarding treatment of Chikungunya-related arthritis. The mainstay of treatment in the acute phase is supportive measures with fluids and antiinflammatory agents (nonsteroidal antiinflammatory drugs [NSAIDs]). Some drugs were found to be effective against CHIKV when tested in vitro, but no antiviral agents have been shown to be effective in human infections.34 There has been documentation of persistence of the virus in nonhuman primates weeks after infection,35 and thus, the use of immunosuppressive agents would not be advised. There are also reports of strong rebound arthritis when corticosteroid treatment is stopped.6

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:Education & TrainingProfessional Topics Tagged with:chikungunyapatient carerheumatologistSafetySteroidssymptomTreatment

Related Articles

    Mosquito-Borne Chikungunya Virus Can Cause Long-Term Arthritis

    September 20, 2018

    Chikungunya is among a group of 16 diseases transmitted through mosquito, tick or flea bites that is of increasing public health concern in the U.S. Although few rheumatologists are likely to diagnose patients with the acute phase of the disease, they may encounter a handful of patients each year who complain of persistent, and often…

    Chikungunya Virus May Lead to Long-Term Joint Pain

    November 18, 2020

    COVID-19 isn’t the only viral infection on the rise across the globe, so is chikungunya, which can cause arthritis-like symptoms and may lead to long-term joint pain.

    Chikungunya Virus Vaccine Shows Promise in Early Clinical Trial

    April 21, 2020

    NEW YORK (Reuters Health)—A new chikungunya virus-like-particle vaccine appears to be safe and immunogenic, according to results from a phase 2 trial. “The phase 2 safety, tolerability and immunogenicity were similar to the data seen in an earlier phase 1 study,” Grace L. Chen, MD, of the National Institutes of Health Vaccine Research Center, Bethesda,…

    Experimental Drug Combination Curbs Chikungunya Arthritis in Mice

    May 16, 2017

    Doctors have had few options to treat the chronic rheumatoid arthritis-like symptoms associated with chikungunya virus infections beyond over-the-counter pain relievers. A recent study in Science Translational Medicine has spurred new optimism by finding that a combination therapy—the anti-rheumatic drug abatacept paired with a chikungunya-neutralizing monoclonal antibody—abolished acute symptoms in infected mice.1 The strategy must…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences